Form 8-K SALIX PHARMACEUTICALS For: Nov 06
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
Salix Pharma (SLXP) Misses Q3 EPS by 3c; Issues Weak Q4 Outlook
November 6, 2014 4:26 PM ESTSalix Pharma (NASDAQ: SLXP) reported Q3 EPS of $1.53, $0.03 worse than the analyst estimate of $1.56. Revenue for the quarter came in at $354.7 million versus the consensus estimate of $394 million.
Salix Pharma sees FY2014 EPS of $5.20, versus the consensus of $6.17. Salix Pharma sees FY2014 revenue of... More
